EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Adarsh Bhimraj iD, Yngve Falck-Ytter, Lindsey R Baden, Roger Bedimo iD, Kelly Cawcutt, Vincent Chi-Chung Cheng, Kara W Chew iD, Kathleen Chiotos iD, Eric S Daar iD, Amy L Dzierba, David V Glidden, Erica J Hardy und 17 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf424 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Adarsh Bhimraj und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: COVID-19, Pre-Exposure Prophylaxis, Infliximab, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Infectious Diseases Society of America, U.S. Government, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Pre-Exposure ProphylaxisInfliximabCOVID-19 Drug TreatmentHumansSARS-CoV-2Critical IllnessPregnancyFemaleImmunocompromised HostAdultSocieties, Medical

Stichwörter der Autor:innen

COVID-19abataceptinfliximabpemivibartvilobelimab

Substanzen

Infliximab

Autor:innen und Institutionen

  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
  • Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.

ORCID-Profile: Adarsh Bhimraj, Roger Bedimo, Kara W Chew, Kathleen Chiotos, Eric S Daar, Greg S Martin, Laura Riley, Shmuel Shoham, Pablo Tebas

Förderung

  • Infectious Diseases Society of America
  • U.S. Government
  • NIH HHS
  • NCI NIH HHS
  • HHS
  • National Cancer Institute
  • National Institutes of Health
  • Department of Health and Human Services

Zitieren

APA

Bhimraj, A., Falck-Ytter, Y., Baden, L. R., Bedimo, R., Cawcutt, K., Cheng, V. C., Chew, K. W., Chiotos, K., Daar, E. S., Dzierba, A. L., Glidden, D. V., Hardy, E. J., Johnson, S., Kim, A. Y., Li, J. Z., MacBrayne, C., Martin, G. S., Nadig, N., Nakamura, M. M., …, & Gandhi, R. T. (2026). 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf424

Vancouver

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf424

BibTeX
@article{Bhimraj2026,
  author = {Bhimraj, Adarsh and Falck-Ytter, Yngve and Baden, Lindsey R and Bedimo, Roger and Cawcutt, Kelly and Cheng, Vincent Chi-Chung and Chew, Kara W and Chiotos, Kathleen and Daar, Eric S and Dzierba, Amy L and Glidden, David V and Hardy, Erica J and Johnson, Steven and Kim, Arthur Y and Li, Jonathan Z and MacBrayne, Christine and Martin, Greg S and Nadig, Nandita and Nakamura, Mari M and Pearson, Jeffrey C and Riley, Laura and Shafer, Robert W and Shoham, Shmuel and Shumaker, Amy Hirsch and Tebas, Pablo and Tien, Phyllis C and Loveless, Jennifer and Morgan, Rebecca L and Gandhi, Rajesh T},
  title = {2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf424}
}
Kostenlos starten →